IRWD
Ironwood Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
4.66 / 10
Netural
Fund flow is strong (7.11/10) with positive inflow ratios, yet trends are negative across all investor sizes. Analyst coverage is thin—only one Buy rating and a low weighted score (2.20), indicating weak consensus and pessimistic market expectations.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-26
InstitutionCitizens
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for IRWD?
- IRWD holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.66/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
